Copyright
©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Apr 21, 2014; 20(15): 4370-4376
Published online Apr 21, 2014. doi: 10.3748/wjg.v20.i15.4370
Published online Apr 21, 2014. doi: 10.3748/wjg.v20.i15.4370
Table 2 Treatment modality of the patients n (%)
| BRAF wild-type (n = 123) | BRAF Mutant (n = 13) | P value | |
| Surgery | 0.737 | ||
| Yes | 93 (75.6) | 9 (69.2) | |
| No | 30 (24.4) | 4 (30.8) | |
| Chemotherapy | |||
| Yes | 119 (96.7) | 11 (84.6) | |
| No | 4 (3.3) | 2 (15.4) | |
| Chemotherapy regimen | 0.441 | ||
| FOLFOX | 97 (82.2) | 9 (81.8) | |
| FOLFIRI | 5 (4.2) | 0 | |
| FL | 7 (5.9) | 2 (15.4) | |
| Xeloda | 8 (6.8) | 0 | |
| SOX | 1 (0.8) | 0 | |
| Target agent use | 0.128 | ||
| No | 91 (74.0) | 8 (61.5) | |
| Bevacizumab | 19 (15.4) | 5 (38.5) | |
| Cetuximab | 13 (10.6) | 0 |
-
Citation: Kim B, Park SJ, Cheon JH, Kim TI, Kim WH, Hong SP. Clinical meaning of
BRAF mutation in Korean patients with advanced colorectal cancer. World J Gastroenterol 2014; 20(15): 4370-4376 - URL: https://www.wjgnet.com/1007-9327/full/v20/i15/4370.htm
- DOI: https://dx.doi.org/10.3748/wjg.v20.i15.4370